Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 12/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.60 |
| ▸ | BRD4 | O60885 | 2/20 | 0.50 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15059366 | 0.79 | S100A4 (0.46) | NPC1RAB9A | |
| SCHEMBL17395816 | 0.75 | CREBBP (1.00) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL30111930 | 0.75 | CREBBP (1.00) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL17395826 | 0.74 | CREBBP (1.00) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL17395803 | 0.74 | CREBBP (0.76) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL17395796 | 0.73 | CREBBP (0.77) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL28506937 | 0.72 | CREBBP (0.69) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL17395867 | 0.72 | CREBBP (0.72) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL17395853 | 0.71 | CREBBP (0.71) | CREBBPHDAC8HDAC1HDAC6BRD4 | |
| SCHEMBL17395818 | 0.71 | CREBBP (1.00) | CREBBPHDAC8HDAC1HDAC6BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016001452-A1 | COMPOUNDS, IN PARTICULAR FOR USE IN THE TREATMENT OF A DISEASE OR CONDITION FOR WHICH A BROMODOMAIN INHIBITOR IS INDICATED | Universität Zürich (CH) | 2016-01-07 | — | — | WO | disclosed |